ReviewRNA (New York, N.Y.)2026
Modulating the cleavage and polyadenylation site: from research tools to therapeutic opportunities.
Review in RNA (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel examples of NMD escape through alternative intronic polyadenylation.NAR genomics and bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Almost all protein-coding and long noncoding genes that are transcribed by RNA polymerase II employ cleavage and polyadenylation (CPA) for 3' end maturation of their nascent RNAs. More than 70% of human mRNA genes display alternative polyadenylation (APA), resulting in expression of isoforms using different CPA sites (also known as poly(A) sites or PAS). APA isoforms often have distinct mRNA metabolism and/or contain variable coding sequences. PAS mutations and genetic variations have been implicated in a growing number of human pathological conditions, underscoring the importance of PAS for proper gene expression. Here we review approaches that modulate the usage of specific PAS and discuss some of their applications in the context of human diseases. We provide our perspectives on current challenges and future directions of strategies of PAS modulation for studying APA isoforms and perturbing gene expression as a therapeutic modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.